The widespread use of anti-TNF in the treatment of patients with IBD has changed the healthcare landscape radically and has led to a major shift in cost profiles.[1] For the first time, we prospectively show in a large longitudinal study that IBD-related costs remain stable over a period of two years. The gene discussed is TNF; the disease is inflammatory bowel disease.